Glecaprevir

Category: pharmacological

Aliases: Component of Mavyret

Pharmacological Mechanism

Pan-genotypic HCV NS3/4A protease inhibitor — blocks viral polyprotein cleavage. Co-formulated with the NS5A inhibitor pibrentasvir as Mavyret for 8-week pan-genotypic HCV cure regimen.

Half-Life (t½)

PO: 6h

Dosing Guidelines

• PO: Typical 300 mg (Range: 300–300 mg)

Target Organ Systems

• immune-hematologic

Pathways It Modulates

• HCV NS3/4A / NS5A / NS5B replication targets (inhibitor) — NS3/4A protease

Chemical Identifiers

• PubChem CID: 66828839
• Formula: C38H46F4N6O9S
• Molecular weight: 838.88 g/mol
• InChIKey: MLSQGNCUYAMAHD-ITNVBOSISA-N
• SMILES: CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C

References

• PMID 37661787